BIOTEST AG (BIO.DE) Stock Price & Overview

FRA:BIO • DE0005227201

Current stock price

42.2 EUR
-0.4 (-0.94%)
Last:

The current stock price of BIO.DE is 42.2 EUR. Today BIO.DE is down by -0.94%. In the past month the price decreased by -0.47%. In the past year, price decreased by -0.94%.

BIO.DE Key Statistics

52-Week Range40.4 - 71.84
Current BIO.DE stock price positioned within its 52-week range.
1-Month Range42 - 43.2
Current BIO.DE stock price positioned within its 1-month range.
Market Cap
1.67B
P/E
N/A
Fwd P/E
27.85
EPS (TTM)
-0.65
Dividend Yield
0.09%

BIO.DE Stock Performance

Today
-0.94%
1 Week
-1.40%
1 Month
-0.47%
3 Months
+1.44%
Longer-term
6 Months +1.44%
1 Year -0.94%
2 Years -0.47%
3 Years -0.94%
5 Years +90.09%
10 Years -39.71%

BIO.DE Stock Chart

BIOTEST AG / BIO Daily stock chart

BIO.DE Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to BIO.DE. When comparing the yearly performance of all stocks, BIO.DE is a bad performer in the overall market: 64.95% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BIO.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BIO.DE. BIO.DE has an average financial health and profitability rating.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIO.DE Earnings

Next Earnings DateAug 4, 2025
Last Earnings DateMay 12, 2025
PeriodQ1 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

BIO.DE Forecast & Estimates

For the next year, analysts expect an EPS growth of 1600% and a revenue growth 11.95% for BIO.DE


Analysts
Analysts45.71
Price TargetN/A
EPS Next Y1600%
Revenue Next Year11.95%

BIO.DE Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

BIO.DE Financial Highlights

Over the last trailing twelve months BIO.DE reported a non-GAAP Earnings per Share(EPS) of -0.65. The EPS decreased by -117.24% compared to the year before.


Income Statements
Revenue(TTM)635.20M
Net Income(TTM)-24.50M
Industry RankSector Rank
PM (TTM) N/A
ROA -1.73%
ROE -4.81%
Debt/Equity 1.26
Chartmill High Growth Momentum
EPS Q2Q%-173.33%
Sales Q2Q%-42.29%
EPS 1Y (TTM)-117.24%
Revenue 1Y (TTM)-15.85%

BIO.DE Ownership

Ownership
Inst Owners0.21%
Shares39.57M
Float570.00K
Ins OwnersN/A
Short Float %N/A
Short RatioN/A

About BIO.DE

Company Profile

BIO logo image Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Company Info

IPO: 1987-10-14

BIOTEST AG

Landsteinerstr. 5

Dreieich HESSEN DE

Employees: 2495

BIO Company Website

Phone: 4961038010

BIOTEST AG / BIO.DE FAQ

What does BIO do?

Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen and currently employs 2,495 full-time employees. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.


Can you provide the latest stock price for BIOTEST AG?

The current stock price of BIO.DE is 42.2 EUR. The price decreased by -0.94% in the last trading session.


Does BIO stock pay dividends?

BIOTEST AG (BIO.DE) has a dividend yield of 0.09%. The yearly dividend amount is currently 0.04.


How is the ChartMill rating for BIOTEST AG?

BIO.DE has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Which stock exchange lists BIO stock?

BIO.DE stock is listed on the Frankfurt Stock Exchange exchange.


Can you provide the PE ratio for BIO stock?

BIOTEST AG (BIO.DE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.65).


Can you provide the upcoming earnings date for BIOTEST AG?

BIOTEST AG (BIO.DE) will report earnings on 2025-08-04.